Loading data for VOR — first visit, this takes a few seconds.

알림

Vor Biopharma Inc. (VOR)

NasdaqGS: VOR · 실시간 가격 · USD

23.28

+0.27 (1.17%)

종가 기준: Aug 18, 2026, 3:59 PM

1.17% (1D)

매수호가	n/a
시가총액	1.38B
매출 (ttm)	n/a
순이익 (ttm)	627.78M
베타	1.72
EPS (ttm)	182.62
P/E (ttm)	0.13
선행 P/E	-6.43
P/B (ttm)	-8.39
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

매도호가	n/a
거래량	994,915
평균 거래량 (20일)	1,172,406
시가	22.82
전일 종가	23.01
일중 범위	22.62 - 23.84
52주 범위	6.50 - 50.20
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

VOR 소개

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 5, 2021

직원 수 76

상장 거래소 NasdaqGS

티커 VOR

웹사이트 https://www.vorbio.com

전체 기업 정보

재무 실적

2025년 Vor Biopharma의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -695.98M로, 495.29% 증가했습니다.

재무제표

어닝 서프라이즈

Vor Biopharma가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.8 예상치 하회 -0.10, 및 99.68% 전년 대비 성장.

다음 실적 발표

Vor Biopharma Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Simply Wall St.

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next

In late June 2026, Vor Biopharma Inc. was added to a broad suite of FTSE Russell indices, including the Russell 2000, 2500, 3000, Microcap, and related growth and value benchmarks. This sweeping inclu...

2개월 전 · Motley Fool

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

2개월 전 · Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

3개월 전 · Simply Wall St.

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

3개월 전 · Zacks

Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est...

2 페이지 중 1

Vor Biopharma Inc. (VOR)